Eli Lilly and Company $LLY Stock Position Lifted by Cookson Peirce & Co. Inc.

Key Points

• Cookson Peirce & Co. Inc. increased its stake in Eli Lilly by 46.8% in the fourth quarter, adding 7,011 shares to bring its total holdings to 21,988 shares valued at about $23.6 million.
• Business momentum remains strong: Lilly’s latest quarterly earnings beat expectations with $8.55 EPS on $19.8 billion in revenue, while revenue rose 55.5% year over year and the company raised its FY 2026 EPS guidance.
• Pipeline and access news are supportive, including CVS Caremark reversing course to cover Zepbound and Lilly expanding its obesity pipeline with a new Phase 2b trial for macupatide–eloralintide, both of which could help future sales growth.

Cookson Peirce & Co. Inc. boosted its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 46.8% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 21,988 shares of the company's stock after purchasing an additional 7,011 shares during the period. Cookson Peirce & Co. Inc.'s holdings in Eli Lilly and Company were worth $23,630,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in LLY. Maryland Capital Advisors Inc. purchased a new position in Eli Lilly and Company during the fourth quarter valued at approximately $25,000. Vermillion & White Wealth Management Group LLC grew its position in Eli Lilly and Company by 84.2% in the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company's stock worth $27,000 after acquiring an additional 16 shares in the last quarter. 10Elms LLP grew its position in Eli Lilly and Company by 33.3% in the third quarter. 10Elms LLP now owns 40 shares of the company's stock worth $31,000 after acquiring an additional 10 shares in the last quarter. E Fund Management Hong Kong Co. Ltd. grew its position in Eli Lilly and Company by 342.9% in the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company's stock worth $32,000 after acquiring an additional 24 shares in the last quarter. Finally, Miller Global Investments LLC bought a new stake in Eli Lilly and Company in the fourth quarter worth approximately $33,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CVS Caremark reversed its earlier exclusion and will now cover Eli Lilly’s Zepbound, a meaningful reimbursement win that could expand patient access and bolster obesity-drug sales. Article Title
• Positive Sentiment: WeightWatchers Med+ is now available through LillyDirect, reinforcing Lilly’s distribution ecosystem and strengthening its leadership in chronic weight management. Article Title
• Positive Sentiment: Lilly announced a new Phase 2b obesity trial for macupatide–eloralintide, adding another potential growth driver to its weight-loss pipeline beyond current GLP-1 products. Article Title
• Positive Sentiment: Jim Cramer highlighted Lilly as a potential winner against competitors, with attention on its new pill version of its weight-loss drug and broader competitive advantages. Article Title
• Positive Sentiment: Analysts and market commentary continue to frame LLY as a long-term winner, citing strong execution, deal-making, and diversification efforts beyond obesity drugs. Article Title
• Neutral Sentiment: Lilly also received coverage around its Phase 3 Libretto-432 cancer study and a $1.9 billion Ascidian partnership, both of which support the pipeline but are longer-term in nature. Article Title
• Neutral Sentiment: Broader health-care sector commentary and stock-screen articles were generally supportive, but they are less likely to be a direct driver of LLY’s move than the CVS and pipeline news. Article Title

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $1,133.15 on Friday. The firm has a fifty day simple moving average of $974.59 and a 200-day simple moving average of $1,013.04. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,166.29. The stock has a market capitalization of $1.07 trillion, a price-to-earnings ratio of 40.25, a PEG ratio of 1.24 and a beta of 0.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping analysts' consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business had revenue of $19.80 billion during the quarter, compared to analysts' expectations of $17.82 billion. During the same period in the previous year, the company earned $3.34 earnings per share. Eli Lilly and Company's revenue for the quarter was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, sell-side analysts expect that Eli Lilly and Company will post 35.8 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, May 15th. Eli Lilly and Company's payout ratio is presently 24.58%.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Daiwa Securities Group boosted their target price on shares of Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the stock a "buy" rating in a research report on Wednesday, February 18th. Guggenheim reissued a "buy" rating and issued a $1,183.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, May 5th. Deutsche Bank Aktiengesellschaft reissued a "buy" rating and issued a $1,285.00 target price on shares of Eli Lilly and Company in a research report on Friday, March 6th. Jefferies Financial Group boosted their target price on shares of Eli Lilly and Company from $1,300.00 to $1,330.00 in a research report on Thursday, May 21st. Finally, Morgan Stanley reissued an "overweight" rating on shares of Eli Lilly and Company in a research report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $1,227.00.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.